Giselle Alexandra Suero Abreu, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sarcoma, Endometrial Stromal | 1 | 2020 | 91 | 0.710 |
Why?
|
Phosphodiesterase 5 Inhibitors | 1 | 2019 | 101 | 0.650 |
Why?
|
Pneumothorax | 1 | 2020 | 379 | 0.590 |
Why?
|
Heart Neoplasms | 1 | 2020 | 374 | 0.580 |
Why?
|
Manganese | 3 | 2015 | 408 | 0.550 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2024 | 2072 | 0.540 |
Why?
|
Amyloidosis | 1 | 2022 | 795 | 0.530 |
Why?
|
Manganese Compounds | 1 | 2014 | 27 | 0.510 |
Why?
|
Vasodilator Agents | 1 | 2019 | 977 | 0.500 |
Why?
|
Contrast Media | 4 | 2017 | 5300 | 0.470 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2019 | 582 | 0.470 |
Why?
|
Melanoma, Experimental | 1 | 2017 | 561 | 0.460 |
Why?
|
Chlorides | 1 | 2014 | 667 | 0.410 |
Why?
|
Bile Duct Neoplasms | 1 | 2017 | 567 | 0.410 |
Why?
|
Cholangiocarcinoma | 1 | 2017 | 516 | 0.410 |
Why?
|
Neoplasms | 5 | 2024 | 21672 | 0.400 |
Why?
|
Endometrial Neoplasms | 1 | 2020 | 1353 | 0.390 |
Why?
|
Heparin | 1 | 2017 | 1637 | 0.360 |
Why?
|
Molecular Imaging | 1 | 2017 | 831 | 0.350 |
Why?
|
Cerebellar Neoplasms | 1 | 2014 | 587 | 0.350 |
Why?
|
Medulloblastoma | 1 | 2014 | 683 | 0.340 |
Why?
|
Heart Failure | 6 | 2023 | 10905 | 0.330 |
Why?
|
Carcinoma, Renal Cell | 2 | 2021 | 3130 | 0.330 |
Why?
|
Quality Improvement | 2 | 2022 | 3746 | 0.300 |
Why?
|
Kidney Neoplasms | 2 | 2021 | 4245 | 0.290 |
Why?
|
Pulmonary Embolism | 1 | 2019 | 2375 | 0.280 |
Why?
|
Anticoagulants | 2 | 2020 | 4599 | 0.270 |
Why?
|
Gated Blood-Pool Imaging | 1 | 2024 | 44 | 0.240 |
Why?
|
Image Enhancement | 1 | 2015 | 2921 | 0.240 |
Why?
|
Anthracyclines | 2 | 2022 | 288 | 0.210 |
Why?
|
Melanoma | 1 | 2020 | 5475 | 0.210 |
Why?
|
Internship and Residency | 1 | 2021 | 5787 | 0.190 |
Why?
|
Skin Neoplasms | 1 | 2020 | 5670 | 0.190 |
Why?
|
Magnetic Resonance Imaging | 4 | 2015 | 35423 | 0.190 |
Why?
|
Esophagitis, Peptic | 1 | 2021 | 78 | 0.190 |
Why?
|
Intracranial Arteriosclerosis | 1 | 2021 | 138 | 0.180 |
Why?
|
Lung Neoplasms | 2 | 2023 | 13096 | 0.180 |
Why?
|
Disease Models, Animal | 2 | 2017 | 18027 | 0.170 |
Why?
|
Symporters | 1 | 2022 | 363 | 0.170 |
Why?
|
Antiphospholipid Syndrome | 1 | 2020 | 173 | 0.170 |
Why?
|
Stroke | 2 | 2021 | 9981 | 0.160 |
Why?
|
Thoracic Surgery, Video-Assisted | 1 | 2020 | 273 | 0.160 |
Why?
|
Infarction, Middle Cerebral Artery | 1 | 2021 | 475 | 0.160 |
Why?
|
Biotinylation | 1 | 2017 | 177 | 0.140 |
Why?
|
Atherosclerosis | 2 | 2023 | 3444 | 0.140 |
Why?
|
Ventricular Function, Left | 3 | 2024 | 3669 | 0.140 |
Why?
|
Receptor, TIE-2 | 1 | 2017 | 178 | 0.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 11493 | 0.140 |
Why?
|
Stroke Volume | 3 | 2024 | 5008 | 0.140 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2021 | 689 | 0.140 |
Why?
|
Cardiovascular System | 1 | 2023 | 832 | 0.130 |
Why?
|
Ischemic Attack, Transient | 1 | 2021 | 934 | 0.130 |
Why?
|
Myocarditis | 1 | 2022 | 771 | 0.130 |
Why?
|
Blood Coagulation | 1 | 2020 | 1127 | 0.120 |
Why?
|
Dyspnea | 1 | 2022 | 1303 | 0.120 |
Why?
|
Secondary Prevention | 1 | 2020 | 1531 | 0.120 |
Why?
|
Subcellular Fractions | 1 | 2014 | 547 | 0.120 |
Why?
|
Atlases as Topic | 1 | 2015 | 237 | 0.120 |
Why?
|
Pneumonectomy | 1 | 2020 | 1094 | 0.120 |
Why?
|
Medical Oncology | 2 | 2023 | 2265 | 0.120 |
Why?
|
Transgenes | 1 | 2017 | 1009 | 0.110 |
Why?
|
Humans | 23 | 2024 | 744220 | 0.110 |
Why?
|
Fatal Outcome | 1 | 2017 | 1849 | 0.110 |
Why?
|
Heart | 2 | 2022 | 4465 | 0.100 |
Why?
|
Imaging, Three-Dimensional | 2 | 2015 | 4044 | 0.100 |
Why?
|
Patient Discharge | 1 | 2023 | 3313 | 0.100 |
Why?
|
Genes, Reporter | 1 | 2014 | 1547 | 0.090 |
Why?
|
Cation Transport Proteins | 1 | 2012 | 327 | 0.090 |
Why?
|
Animals, Newborn | 1 | 2015 | 2726 | 0.090 |
Why?
|
Software | 1 | 2024 | 4442 | 0.090 |
Why?
|
Neoplasms, Experimental | 1 | 2014 | 1275 | 0.090 |
Why?
|
Education, Medical, Graduate | 1 | 2021 | 2291 | 0.080 |
Why?
|
Disease Progression | 2 | 2017 | 13280 | 0.080 |
Why?
|
Kinetics | 1 | 2017 | 6474 | 0.080 |
Why?
|
Pyrimidines | 1 | 2021 | 2940 | 0.080 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2023 | 11732 | 0.080 |
Why?
|
Early Detection of Cancer | 1 | 2022 | 3086 | 0.080 |
Why?
|
Brain | 1 | 2015 | 26413 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1670 | 0.080 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 3256 | 0.070 |
Why?
|
Sodium | 2 | 2023 | 1623 | 0.070 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 4841 | 0.070 |
Why?
|
Cardiovascular Diseases | 2 | 2022 | 15161 | 0.070 |
Why?
|
HIV Infections | 2 | 2022 | 16718 | 0.070 |
Why?
|
Cross-Sectional Studies | 2 | 2024 | 25043 | 0.070 |
Why?
|
Receptors, Cell Surface | 1 | 2014 | 2867 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2021 | 5529 | 0.060 |
Why?
|
Mice, Transgenic | 1 | 2017 | 9735 | 0.060 |
Why?
|
Retrospective Studies | 5 | 2024 | 77426 | 0.060 |
Why?
|
Endothelial Cells | 1 | 2017 | 3478 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2022 | 9230 | 0.060 |
Why?
|
Gene Expression | 1 | 2017 | 7799 | 0.060 |
Why?
|
Ultrasonography | 1 | 2017 | 5982 | 0.060 |
Why?
|
Middle Aged | 8 | 2023 | 213367 | 0.060 |
Why?
|
Repressor Proteins | 1 | 2014 | 3023 | 0.060 |
Why?
|
Monocytes | 2 | 2022 | 2594 | 0.060 |
Why?
|
Atrial Fibrillation | 1 | 2021 | 5034 | 0.050 |
Why?
|
Myocardial Infarction | 1 | 2023 | 11728 | 0.050 |
Why?
|
Mice, Inbred C57BL | 2 | 2017 | 21824 | 0.050 |
Why?
|
Animals | 5 | 2017 | 168788 | 0.050 |
Why?
|
Cell Proliferation | 1 | 2017 | 10480 | 0.050 |
Why?
|
Bacterial Proteins | 1 | 2014 | 3849 | 0.050 |
Why?
|
Osteopontin | 1 | 2022 | 296 | 0.050 |
Why?
|
Female | 9 | 2023 | 380197 | 0.050 |
Why?
|
Mice | 4 | 2015 | 81178 | 0.050 |
Why?
|
Glucose | 2 | 2023 | 4396 | 0.050 |
Why?
|
Thorax | 1 | 2023 | 547 | 0.050 |
Why?
|
Prescriptions | 1 | 2022 | 387 | 0.040 |
Why?
|
Mice, Knockout | 1 | 2014 | 14556 | 0.040 |
Why?
|
Receptors, Chemokine | 1 | 2022 | 669 | 0.040 |
Why?
|
American Heart Association | 1 | 2023 | 1056 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13668 | 0.040 |
Why?
|
Orbit | 1 | 2021 | 426 | 0.040 |
Why?
|
Aftercare | 1 | 2023 | 866 | 0.040 |
Why?
|
Troponin T | 1 | 2022 | 753 | 0.040 |
Why?
|
Treatment Outcome | 2 | 2021 | 63119 | 0.040 |
Why?
|
Fibrosis | 1 | 2022 | 2029 | 0.030 |
Why?
|
Molecular Probe Techniques | 1 | 2014 | 119 | 0.030 |
Why?
|
Time Factors | 1 | 2015 | 40063 | 0.030 |
Why?
|
Cholesterol | 1 | 2022 | 2911 | 0.030 |
Why?
|
Molecular Probes | 1 | 2014 | 316 | 0.030 |
Why?
|
Male | 5 | 2023 | 350027 | 0.030 |
Why?
|
Administration, Oral | 1 | 2020 | 3913 | 0.030 |
Why?
|
Adult | 3 | 2023 | 214035 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2023 | 8628 | 0.020 |
Why?
|
Protein Engineering | 1 | 2014 | 540 | 0.020 |
Why?
|
Recovery of Function | 1 | 2021 | 2925 | 0.020 |
Why?
|
Patient Readmission | 1 | 2023 | 3114 | 0.020 |
Why?
|
Biopsy | 1 | 2021 | 6757 | 0.020 |
Why?
|
Brain Chemistry | 1 | 2012 | 982 | 0.020 |
Why?
|
Echocardiography | 1 | 2020 | 5103 | 0.020 |
Why?
|
Length of Stay | 1 | 2021 | 6308 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2021 | 5316 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2022 | 57768 | 0.020 |
Why?
|
Comorbidity | 1 | 2021 | 10387 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2022 | 15070 | 0.020 |
Why?
|
Databases, Factual | 1 | 2021 | 7730 | 0.020 |
Why?
|
Aged | 3 | 2023 | 163253 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12961 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2014 | 4201 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2023 | 21752 | 0.020 |
Why?
|
United States | 2 | 2023 | 69867 | 0.020 |
Why?
|
Risk Factors | 2 | 2021 | 72280 | 0.010 |
Why?
|
Incidence | 1 | 2021 | 20945 | 0.010 |
Why?
|
Protein Binding | 1 | 2014 | 9392 | 0.010 |
Why?
|
Cohort Studies | 1 | 2023 | 40559 | 0.010 |
Why?
|
Risk Assessment | 1 | 2021 | 23337 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2014 | 16687 | 0.010 |
Why?
|
Prospective Studies | 1 | 2022 | 53280 | 0.010 |
Why?
|
Young Adult | 1 | 2021 | 56436 | 0.010 |
Why?
|
Adolescent | 1 | 2021 | 85759 | 0.010 |
Why?
|